First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

Summary

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359. The study is split into different modules which will look at AZD8359 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels and dosing schedules of AZD8359 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD8359 doses in a larger group of participants (dose expansion).

Timeline

Start

2026-05-18

Primary completion

2027-11-17

Completion

2027-11-17

Drugs

Indications